U.S. markets closed
  • S&P 500

    4,152.10
    -36.33 (-0.87%)
     
  • Dow 30

    34,269.16
    -473.66 (-1.36%)
     
  • Nasdaq

    13,389.43
    -12.43 (-0.09%)
     
  • Russell 2000

    2,206.99
    -5.71 (-0.26%)
     
  • Crude Oil

    65.45
    +0.53 (+0.82%)
     
  • Gold

    1,838.40
    +0.80 (+0.04%)
     
  • Silver

    27.75
    +0.25 (+0.92%)
     
  • EUR/USD

    1.2151
    +0.0016 (+0.13%)
     
  • 10-Yr Bond

    1.6240
    +0.0220 (+1.37%)
     
  • GBP/USD

    1.4147
    +0.0026 (+0.18%)
     
  • USD/JPY

    108.5990
    -0.2420 (-0.22%)
     
  • BTC-USD

    56,705.09
    +1,108.65 (+1.99%)
     
  • CMC Crypto 200

    1,522.77
    +1,280.09 (+527.48%)
     
  • FTSE 100

    6,947.99
    -175.69 (-2.47%)
     
  • Nikkei 225

    28,608.59
    -909.71 (-3.08%)
     

INVESTIGATION ALERT - Nationally Ranked Shareholder Rights Firm Labaton Sucharow is Investigating ChemoCentryx, Inc. for Potential Securities Fraud Claims

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / May 11, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, is investigating whether ChemoCentryx, Inc. (NASDAQ:CCXI) committed securities fraud.

On May 4, 2021, the U.S. Food and Drug Administration released a "Briefing Document" concerning ChemoCentryx's drug candidate avacopan, which is in development for the treatment of adult patients with anti-neutrophil cytoplasmic autoantibody vasculitis. In this Briefing Document, the FDA wrote that its review team "has identified several areas of concern, raising uncertainties about the interpretability of the data" submitted as part of ChemoCentryx's application, as well as concerns with "the clinical meaningfulness of these results."

On this news, shares have plummeted by approximately 60% during intraday trading on May 4, 2021. Investors who have lost money on their Aterian investment - whether or not they have sold that investment - are potentially eligible.

Labaton Sucharow is investigating the potential filing of a securities class action lawsuit to attempt to recover losses on behalf of investors who have lost money.

If you've lost money on your investment, please contact David J. Schwartz using the toll-free number (800) 321-0476 or via email at david@labaton.com.

About the Firm

Labaton Sucharow LLP is one of the world's leading complex litigation firms representing clients in securities, antitrust, corporate governance and shareholder rights, and consumer cybersecurity and data privacy litigation. Labaton Sucharow has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, NY, Wilmington, DE, and Washington, D.C. More information about Labaton Sucharow is available at http://www.labaton.com.

Contact

David J. Schwartz
(800) 321-0476
david@labaton.com

SOURCE: Labaton Sucharow LLP



View source version on accesswire.com:
https://www.accesswire.com/646399/INVESTIGATION-ALERT--Nationally-Ranked-Shareholder-Rights-Firm-Labaton-Sucharow-is-Investigating-ChemoCentryx-Inc-for-Potential-Securities-Fraud-Claims